The antidiabetic agent, gliclazide, reduces high insulin-enhanced neutrophil-transendothelial migration through direct effects on the endothelium. - Okouchi,M.; Okayama,N.; Omi,H.; Imaeda,K.; Fukutomi,T.; Nakamura,A. (Diabetes Metab Res Rev, 2004)